U.S. Specialty Stores Stock News

If you are wondering whether DICK'S Sporting Goods at around US$229 per share still offers value, or if most of the easy gains are already behind it, this article helps you frame that question clearly. The stock has been relatively flat over the last 7 days with a 0.6% decline, but its 21.1% return over 30 days and 23.7% return over 1 year provide useful context for anyone thinking about entry or exit points. Recent attention on the company has focused on how it is positioned as a major US...

MACOM Technology Solutions Holdings recently entered into long-term supply agreements with IQE plc for epitaxial services across multiple technologies and committed £45 million through equity and convertible loan notes, gaining board representation at IQE. This move deepens MACOM’s access to specialized compound semiconductor capacity while aligning it more closely with a key supplier’s governance and capital structure. Next, we’ll examine how MACOM’s long-term IQE supply deal and board seat...

In April 2026, Synchrony Financial reported higher first-quarter net interest income of US$4,635 million and net income of US$805 million, while also unveiling an expanded buyback authorization of up to US$6.50 billion, a planned increase in its common dividend to US$0.34 per share from the third quarter, and multiple new co-branded and private-label card programs with Chico’s FAS and RH powered by its PRISM credit decisioning platform. This combination of earnings growth, enhanced...

Wondering if Viking Therapeutics at around US$33 is still offering value or if most of the story is already priced in? This article focuses squarely on what the numbers say about its valuation. The stock has seen a mix of shorter term weakness and longer term strength, with a 7.2% decline over the past week, a 1.4% gain over the last 30 days, a 6.9% decline year to date, and a 27.2% return over the past year. Recent attention on Viking Therapeutics has been shaped by ongoing developments...

Nucor Corporation recently reported past first-quarter 2026 results showing sales of US$9,496 million and net income of US$743 million, with basic and diluted earnings per share from continuing operations of US$3.23, all higher than the prior year period. Management highlighted that strong order demand, supportive U.S. steel tariffs, and what the CEO calls the best import backdrop in 30 years are reinforcing Nucor’s current operating strength. We’ll now examine how Nucor’s sharply higher...

Covista (CVSA) is back in focus after expanding its healthcare AI credentials with Google Cloud to all five institutions and outlining plans to pilot a fully integrated, AI powered classroom experience later this year. See our latest analysis for Covista. That partnership news lands at a time when Covista’s share price, now at $112.39, shows a mixed picture, with a 4.42% 1 day share price return but a softer 30 day share price return of 1.94%, while long term total shareholder returns over...

In April 2026, First Mid Bancshares entered into a Business Loan Agreement with Bankers' Bank, securing a US$15,000,000 revolving line of credit maturing in 2027 and a US$20,000,000 term loan maturing in 2029, both at variable interest rates and backed by a negative pledge over its bank subsidiary. An interesting aspect of this financing is the use of the new term loan to pay down existing subordinated debt, which reshapes the company’s funding mix and interest-rate exposure. Next, we’ll...

Cloud AI is positioned at a critical junction, as its influence on Wall Street has been marked by increased infrastructure investments and heightened valuations. Dan Herbatschek, CEO of Ramsey Theory Group, suggests this period could be transformative as major tech firms, including Microsoft, Meta, Amazon, and Alphabet, report their earnings, driving scrutiny towards the return on AI investments. Investors are beginning to demand more than ambitious AI narratives; they seek tangible financial...

Why Bread Financial Holdings (BFH) is on investors’ radar Bread Financial Holdings (BFH) has drawn attention after a strong share price move, with the stock up about 22% over the past month and 27% over the past 3 months. That performance, combined with a value score of 5 and an intrinsic discount estimate of about 39%, is prompting investors to take a closer look at how the business and its current valuation line up. See our latest analysis for Bread Financial Holdings. Short term momentum...

Revolution Medicines (RVMD) is back in focus after reporting what it called unprecedented overall survival benefit from its Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer, with full data headed to an ASCO Plenary Session. See our latest analysis for Revolution Medicines. Investors have reacted strongly to the recent clinical updates and financing, with Revolution Medicines posting a 30 day share price return of 42.33% and a year to date share price return of...

PVH stock moves after recent performance surge PVH (PVH) has drawn fresh attention after a strong share price move over the past month, with the stock up about 41%, prompting investors to reassess how current fundamentals line up with this shift. See our latest analysis for PVH. Set against a recent 40.7% 30 day share price return and a 49.8% 90 day share price return, PVH’s 31.6% one year total shareholder return suggests momentum has picked up after a weaker five year total shareholder...

Corcept Therapeutics announced that it will present new pivotal Phase 3 ROSELLA data on Lifyorli (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting, following the regimen’s March 2026 FDA approval and NCCN Guideline inclusion as a preferred option. Lifyorli’s status as the first FDA-approved selective glucocorticoid receptor antagonist, with no biomarker requirement and oral dosing around nab-paclitaxel infusions, highlights a...

Rambus (RMBS) just released first quarter 2026 results in line with expectations, highlighting solid cash generation and growing demand tied to AI data center workloads, along with its new SOCAMM2 memory chipset launch for AI servers. See our latest analysis for Rambus. The stock has been volatile around these updates, with a 57.48% 1 month share price return and a 10.79% 1 day pullback. The 1 year total shareholder return of 186.81% and 5 year total shareholder return of about 6.4x indicate...

Boyd Gaming (BYD) is back in focus after its Q1 2026 report showed flat year on year sales, an adjusted earnings per share miss, and fresh commentary on regional growth, cost pressures, and ongoing construction in Las Vegas. See our latest analysis for Boyd Gaming. Boyd Gaming shares have climbed, with a 9.19% 1 month share price return and a 27.50% 1 year total shareholder return. This suggests that recent earnings, buybacks, and capital projects are influencing how the market views future...

Earlier in April 2026, Leidos received a new US$617 million U.S. Army award to build additional Indirect Fire Protection Capability Increment 2 launchers, bringing its IFPC Inc. 2 production contracts to nearly US$1.20 billion with more than 100 launchers committed and funding extending potential orders through 2029. This award, alongside Leidos’ early delivery of the first IFPC Inc. 2 test launcher, reinforces its role in next-generation, modular air and missile defense within its NorthStar...

Last week, The InterGroup Corporation ( NASDAQ:INTG ) insiders, who had purchased shares in the previous 12 months were...

The fact that multiple STERIS plc ( NYSE:STE ) insiders offloaded a considerable amount of shares over the past year...

Citizens Community Bancorp (CZWI) has reported Q1 2026 revenue of US$15.4 million and basic EPS of US$0.39, with trailing twelve month EPS at US$1.53 on revenue of US$61.3 million. Over the past year, revenue on a trailing basis has moved from US$59.6 million to US$61.3 million, while TTM EPS has shifted from US$1.34 to US$1.53. This sets up a results season in which improving profit margins and faster earnings growth are front and center for investors assessing the bank's earnings power. See...

Earlier this year, Compass reported its strongest quarter on record, with higher revenue and improved adjusted EBITDA as it advances its mission to digitize U.S. residential brokerage. However, the company did not meet adjusted operating income expectations, highlighting an important tension between top-line momentum and progress toward profitability. We’ll now examine how record results alongside an adjusted operating income shortfall may influence Compass’s broader investment...

In April 2026, ICF International amended and restated its credit agreement, maintaining a US$600.0 million revolving facility, increasing its term loan to US$450.0 million, preserving a US$400.0 million delayed draw term loan, and extending the facility’s maturity to April 10, 2031, while also participating in industry events such as Data Center World and a Washington D.C. C-level technology summit. This refreshed credit structure, which includes a first-priority security interest over...

Capital raise plans put VisionWave Holdings (VWAV) in focus VisionWave Holdings (VWAV) has drawn fresh attention after filing a shelf registration for up to US$44.15m of common stock, a move that gives the company flexibility to tap equity markets. See our latest analysis for VisionWave Holdings. The shelf registration and recent board appointment come after a sharp 38.98% 90 day share price decline and a 43.14% 1 year total shareholder return loss, even as the latest close sits at US$6.34...

What Elevance Health investors may be watching now Elevance Health (ELV) has drawn attention after recent share moves, with the stock showing a 3.3% gain over the past week and a 24.4% return over the past month. See our latest analysis for Elevance Health. That short burst of momentum, including an 11.5% 7 day share price return and 24.4% 30 day share price return, contrasts with a weaker 12.1% 1 year total shareholder return. This suggests sentiment has only recently improved. If Elevance...

Wondering if STAG Industrial is offering fair value at around US$39.48, or if the current price is leaving something on the table for new investors. The stock has had a mixed run recently, with a 1% decline over the last 7 days, a 9.4% gain over the last 30 days, and returns of 6.9% year to date and 25.3% over the last year. Recent coverage has focused on STAG Industrial's position in the industrial real estate space and how investors are weighing it against wider REIT options. This context...

United States Antimony (UAMY) has restarted mining at its Stibnite Hill property in Thompson Falls, Montana after a winter weather pause, while also reporting a 163% revenue increase for fiscal 2025. See our latest analysis for United States Antimony. The latest production restart and revenue jump sit alongside sharp moves in the stock, with a 1 day share price return of 14.78%, a 30 day share price return of 27.77% and a 1 year total shareholder return of 232.74%. This points to momentum...